Abstract
Reduced intensity stem-cell transplantation (RIST) has been developed as a novel curative option for advanced hematologic diseases. Its minimal toxicity has made transplantation possible for patients of advanced age or having organ dysfunction. Young patients without comorbidity can undergo RIST in the outpatient setting. Fungal infection remains an important complication in RIST. Since the prognosis of fungal infection is poor, prophylaxis is critical for its management; given recent progression in RIST management, the strategy of infectious prophylaxis has also changed. Equipment in the hospital is important for fungal infection; however, the median day of the development of fungal infection is day 100, the stage at which most of patients are followed as outpatients. The focus of fungal management after RIST is oral antifungals rather than in-hospital equipment. Various antifungals have recently been developed and applied to clinical use. A major change in antifungal management will probably occur in several years.
